Intrathecal antibodies cross-react with EBV BRRF2 and human antigens in multiple sclerosis

Multiple sclerosis is a condition where the body's own immune system mistakenly attacks the protective covering of nerve fibers in the brain and spinal cord. This damage disrupts the signals that travel between the brain and the rest of the body, leading to a wide range of symptoms. A key feature of this disease is the presence of specific antibodies, which are proteins made by immune cells to fight off invaders, found floating in the fluid that surrounds the brain and spinal cord. While scientists have long known that these antibodies are produced inside the central nervous system, the exact targets they are aimed at have remained a mystery. Understanding what these antibodies are attacking is crucial, because it could reveal the trigger that starts the disease and help doctors distinguish between different types of the condition.

Researchers set out to solve this puzzle by looking closely at the antibodies found in the spinal fluid of people with multiple sclerosis. They collected samples from forty individuals with the disease and compared them with samples from eighty-three people without it. To see what these antibodies were binding to, the team used a method that acts like a massive search, testing the antibodies against thousands of tiny protein fragments from viruses and human cells. This approach allowed them to map out the specific targets of the immune response with great precision. They discovered that while the antibodies in multiple sclerosis patients were generally broad and reacted with many different things, a specific group of patients shared a common pattern. These individuals produced antibodies that latched onto a particular piece of a protein from the Epstein-Barr virus, a very common virus that infects most people.

What made this finding particularly significant was that the antibodies did not stop at the virus. The specific piece of the viral protein that triggered the response looked very similar to pieces of proteins found naturally in the human brain and spinal cord. The researchers found that the antibodies created to fight this viral fragment also stuck to human proteins, specifically ones named TRIM71 and RTN2. This suggests a case of mistaken identity, where the immune system, after reacting to the virus, continues to attack the body's own tissues because they share a similar shape. To confirm how common this reaction was, the team tested a much larger group of people, including nine hundred and nine individuals with multiple sclerosis and three hundred and eleven without the disease. They found that antibodies targeting this specific viral piece were present in about eight percent of the people with multiple sclerosis, but in less than one percent of the control group.

The study also showed that people who had these specific antibodies in their blood were more likely to have high levels of antibody production inside their central nervous system. This connection strengthens the idea that this specific immune response is a distinct feature of the disease in these patients. By identifying this shared target, the researchers have defined a clear signature that separates a subset of multiple sclerosis patients from others. This discovery does not explain the cause of the disease for everyone, but it provides a precise marker that could help doctors group patients more accurately in the future. It offers a clearer view of how a common viral infection might interact with human biology to drive the disease in some individuals, moving the field closer to understanding the complex mechanics of multiple sclerosis.